Literature DB >> 10529370

A novel compound heterozygote (FAP ATTR Arg104His/ATTR Val30Met) with high serum transthyretin (TTR) and retinol binding protein (RBP) levels.

H Terazaki1, Y Ando, S Misumi, M Nakamura, E Ando, N Matsunaga, S Shoji, M Okuyama, H Ideta, K Nakagawa, T Ishizaki, M Ando, M J Saraiva.   

Abstract

A 64-year-old Japanese male suffering from very slowly progressive amyloidosis was studied by immunohistopathologic, mass spectrometric, and molecular genetic methods. After confirming the immunoreactivity of transthyretin (TTR) in the amyloid deposits using an anti-TTR polyclonal antibody, matrix-assisted laser desorption ionization/time-of-flight-mass spectrometry (MALDI/TOF-MS) was employed to look for the presence of variant TTR(s) in the serum. Two variant forms of TTR, one with a molecular weight 32 Da greater and another with a molecular weight 19 Da less than that of normal TTR encoded by the two respective alleles, were detected in this patient. Direct sequence analysis confirmed the presence of a double substitution: one at codon 30 from GTG (Val) to ATG (Met) and the other at codon 104 from CGC (Arg) to CAC (His) in the two alleles. MALDI/TOF-MS of the parents of the proband revealed that his father was a heterozygote of ATTR Arg104His and his mother was a heterozygote of ATTR Val30Met. The total TTR and retinol binding protein (RBP) concentrations in the serum samples of the proband were very high compared with those of FAP ATTR Val30Met patients and control subjects. We report here a new compound heterozygote in the TTR gene with familial amyloidotic polyneuropathy (FAP). Copyright 1999 Academic Press.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10529370     DOI: 10.1006/bbrc.1999.1514

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  10 in total

1.  Enthalpy-Driven Stabilization of Transthyretin by AG10 Mimics a Naturally Occurring Genetic Variant That Protects from Transthyretin Amyloidosis.

Authors:  Mark Miller; Arindom Pal; Wabel Albusairi; Hyun Joo; Beverly Pappas; Md Tariqul Haque Tuhin; Dengpan Liang; Raghavendra Jampala; Fang Liu; Jared Khan; Marjon Faaij; Miki Park; William Chan; Isabella Graef; Robert Zamboni; Neil Kumar; Jonathan Fox; Uma Sinha; Mamoun Alhamadsheh
Journal:  J Med Chem       Date:  2018-08-22       Impact factor: 7.446

Review 2.  Liver transplantation and new therapeutic approaches for familial amyloidotic polyneuropathy (FAP).

Authors:  Yukio Ando
Journal:  Med Mol Morphol       Date:  2005-09       Impact factor: 2.309

3.  Three Newly Recognized Likely Pathogenic Gene Variants Associated with Hereditary Transthyretin Amyloidosis.

Authors:  Jignesh K Patel; Andrew M Rosen; Adam Chamberlin; Benjamin Feldmann; Christian Antolik; Heather Zimmermann; Tami Johnston; Arvind Narayana
Journal:  Neurol Ther       Date:  2022-08-06

4.  Decreased clearance of serum retinol-binding protein and elevated levels of transthyretin in insulin-resistant ob/ob mice.

Authors:  Nimesh Mody; Timothy E Graham; Yuki Tsuji; Qin Yang; Barbara B Kahn
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-02-19       Impact factor: 4.310

5.  Effects of tafamidis on transthyretin stabilization and clinical outcomes in patients with non-Val30Met transthyretin amyloidosis.

Authors:  Giampaolo Merlini; Violaine Planté-Bordeneuve; Daniel P Judge; Hartmut Schmidt; Laura Obici; Stefano Perlini; Jeff Packman; Tara Tripp; Donna R Grogan
Journal:  J Cardiovasc Transl Res       Date:  2013-10-08       Impact factor: 4.132

Review 6.  Transthyretin-related familial amyloidotic polyneuropathy-Progress in Kumamoto, Japan (1967-2010)-.

Authors:  Shukuro Araki; Yukio Ando
Journal:  Proc Jpn Acad Ser B Phys Biol Sci       Date:  2010       Impact factor: 3.493

7.  Cavity filling mutations at the thyroxine-binding site dramatically increase transthyretin stability and prevent its aggregation.

Authors:  Ricardo Sant'Anna; Maria Rosário Almeida; Nathalia Varejāo; Pablo Gallego; Sebastian Esperante; Priscila Ferreira; Alda Pereira-Henriques; Fernando L Palhano; Mamede de Carvalho; Debora Foguel; David Reverter; Maria João Saraiva; Salvador Ventura
Journal:  Sci Rep       Date:  2017-03-24       Impact factor: 4.379

8.  Urinary Transthyretin as a Biomarker in ATTRv Val50Met Amyloidosis.

Authors:  Hiroaki Matsushita; Yohei Misumi; Teruaki Masuda; Masamitsu Okada; Fumika Inoue; Mitsuharu Ueda; Yukio Ando
Journal:  Pathophysiology       Date:  2022-06-29

9.  Amyloidogenicity assessment of transthyretin gene variants.

Authors:  Nicolai B Grether; Felix Napravnik; Thomas Imhof; Reinhold P Linke; Jan H Bräsen; Jessica Schmitz; Maike Dohrn; Christian Schneider; Martin K R Svačina; Jörg Stetefeld; Manuel Koch; Helmar C Lehmann
Journal:  Ann Clin Transl Neurol       Date:  2022-07-29       Impact factor: 5.430

Review 10.  Review on the Structures and Activities of Transthyretin Amyloidogenesis Inhibitors.

Authors:  Xiaohua Guo; Zhaowen Liu; Yizhou Zheng; Yamei Li; Linfu Li; Hai Liu; Zhixi Chen; Longhuo Wu
Journal:  Drug Des Devel Ther       Date:  2020-03-10       Impact factor: 4.162

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.